Floatz logo

Bezuclastinib

Metastatic Malignant Neoplasm

Cogent Biosciences, Inc.Small moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

272 Active assets in the Metastatic Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
Fluorouracilum
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
Nivestim
Mayo Clinic
Phase 3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Bezuclastinib is also rated in:

gastrointestinal stromal tumorActive
BB
Indicative · Phase 3
66 / 100
View asset →
systemic mastocytosisActive
CCC
Indicative · Phase 2
53 / 100
View asset →
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →